Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
1999 1
2002 1
2004 1
2006 2
2010 1
2015 1
2016 1
2020 1
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Advances in pharmacologic strategies for cancer cachexia.
Madeddu C, Mantovani G, Gramignano G, Macciò A. Madeddu C, et al. Expert Opin Pharmacother. 2015;16(14):2163-77. doi: 10.1517/14656566.2015.1079621. Epub 2015 Sep 2. Expert Opin Pharmacother. 2015. PMID: 26330024 Review.
Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA).
Testino G, Vignoli T, Patussi V, Allosio P, Amendola MF, Aricò S, Baselice A, Balbinot P, Campanile V, Fanucchi T, Macciò L, Meneguzzi C, Mioni D, Parisi M, Renzetti D, Rossin R, Gandin C, Bottaro LC, Caio G, Lungaro L, Zoli G, Scafato E, Caputo F. Testino G, et al. Addict Biol. 2022 Jan;27(1):e13090. doi: 10.1111/adb.13090. Epub 2021 Sep 16. Addict Biol. 2022. PMID: 34532923 Free PMC article.
The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibili …
The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in inter …
Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?".
Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J, Mo C, O'Gorman P, Yanik G, Palomo M, Diaz-Ricart M, Moraleda JM; DEFACOVID Study Group. Richardson E, et al. J Thromb Haemost. 2020 Nov;18(11):3111-3113. doi: 10.1111/jth.15088. J Thromb Haemost. 2020. PMID: 32860297 Free PMC article. No abstract available.
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G, Macciò A, Curreli L, Lampis B, Ghiani M, Bianchi A, Contu P. Mantovani G, et al. Oncol Rep. 1998 Jan-Feb;5(1):273-80. doi: 10.3892/or.5.1.273. Oncol Rep. 1998. PMID: 9458381 Clinical Trial.
A good control of acute emesis had a highly positive predictive value of delayed emesis for both treatments without significant difference between them (CR 85% for M + D and 82% for 5-HT3-RA; ME 88% for M + D and 92% for 5-HT3-RA). The failure (F) on acute emesis ha …
A good control of acute emesis had a highly positive predictive value of delayed emesis for both treatments without significant difference b …
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.
Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R. Mantovani G, et al. Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1651-9. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15466983 Clinical Trial.
PATIENTS AND METHODS: On the basis of our previously published studies and clinical experience, we have developed an innovative approach consisting of diet with high polyphenol content (400 mg), p.o. pharmaconutritional support enriched with n - 3 fatty acids (eicosapentaenoic ac …
PATIENTS AND METHODS: On the basis of our previously published studies and clinical experience, we have developed an innovative approach con …
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. Mantovani G, et al. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1030-4. doi: 10.1158/1055-9965.EPI-05-0538. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16702388 Clinical Trial.
The integrated treatment consisted of diet with high polyphenols content (400 mg), antioxidant treatment (300 mg/d alpha-lipoic acid + 2.7 g/d carbocysteine lysine salt + 400 mg/d vitamin E + 30,000 IU/d vitamin A + 500 mg/d vitamin C), and phar …
The integrated treatment consisted of diet with high polyphenols content (400 mg), antioxidant treatment (300 mg/d alpha-lipoic acid …
15 results